Pulmonary alveolar proteinosis complicated with nocardiosis: A case report and review of the literature

Table 1 Pulmonary function testing before and after treatment

	August 2018	April 2019	December 2019
FEV1 in L	3.12	3.18	3.43
FVC in L	3.2	3.3	3.8
FEV1/FVC, %	97.5	96.4	90.3
FEV1/pred, %	90.6	92.4	95.3
FVC/pred, %	77.0	79.3	91.3
DLCO SB in mmol/min/kPa	4.50	4.74	7.62
DLCO SB/pred, %	46.4	48.9	78.6

DLCO SB: Diffusing capacity of the lungs single-breath; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; pred: Predictive value.

Table 2 Drug-susceptibility testing

Drug	Sensibility	Result in μg/mL	Method
Amoxicillin	S	1	MIC
Ceftriaxone sodium	S	1	MIC
Imipenem	S	2	MIC
Clarithromycin	R	> 64	MIC
Linezolid	S	1	MIC
Minocycline	S	1	MIC
Ciprofloxacin	S	8	MIC
Moxifloxacin	R	4	MIC
Tobramycin	S	1	MIC
Amikacin	S	1	MIC
Sulfamethoxazole	S	0.5	MIC

MIC: Minimum inhibitory concentration; R: Resistant; S: Sensitive.

Table 3 Efficacy before and after treatment

	August 2018	April 2019	December 2019
Dyspnea index	2	2	0
Supplemental O2 in L/min	5	3	0
PaO2 in mmHg	50.7	62.6	95.8
SaO2 in mmHg	86.1	91.5	97

Dyspnea index: 0: Asymptomatic while climbing stairs; 1: Symptomatic while climbing stairs; 2: Symptomatic after walking 100 m on flat ground; 3: Symptomatic with the least effort (e.g., talking, getting dressed); 4: Symptomatic in bed, at rest. PaO₂: Arterial partial pressure of oxygen (blood gas); SaO₂: Arterial oxygen saturation (blood gas).